Gabapentin
Product Images NDC 42549-537

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 42549-537). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Stat Rx Usa Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gabapentin Tablets Usp 600mg Label (Gabapentin 600 mg 42549 Label)

GABAPENTIN 600 mg tablet bottle label, packaged and distributed by STAT Rx USA LLC in Gainesville, GA. The label states it is a generic for Neurontin, with package size of 60 tablets. NDC 42549-537-60 is shown along with manufacturer information for Teva Pharmaceuticals USA, Sellersville, PA.*

FDA Label Image

Structural Formula (E8695a1d Fd85 4639 81ff Bab10676ebd9 01)

Chemical structure diagram depicting the active ingredient gabapentin, showing its molecular configuration with a cyclohexane ring and functional groups including amine and carboxyl groups.*

FDA Label Image

Figure 1 (E8695a1d Fd85 4639 81ff Bab10676ebd9 02)

A line graph comparing mean pain scores over 8 weeks between placebo and Gabapentin 3600 mg/day groups. The x-axis shows weeks from baseline to week 8, and the y-axis shows mean pain score from 0 to 10. The graph marks a 4-week dose titration period followed by a 4-week fixed dose period, with Gabapentin showing a significant reduction in pain scores versus placebo (p < 0.01).*

FDA Label Image

Figure 2 (E8695a1d Fd85 4639 81ff Bab10676ebd9 03)

Line graph showing mean pain score over 7 weeks comparing placebo and two doses of Gabapentin (1800 mg/day and 2400 mg/day). The study includes a 3-week dose titration period followed by a 4-week fixed dose period. Gabapentin groups show a greater reduction in mean pain score than placebo, with statistical significance noted (p < 0.01).*

FDA Label Image

Figure 3 (E8695a1d Fd85 4639 81ff Bab10676ebd9 04)

A bar chart showing percentage of responders at endpoint for two studies comparing placebo (PBO) and gabapentin (GBP) at different doses. Study 1 compares PBO versus GBP 3600 mg, with responder rates of 12% and 29%, respectively. Study 2 compares PBO with GBP 1800 mg and GBP 2400 mg, with responder rates of 14%, 32%, and 34%, respectively. Significance levels indicated by asterisks for GBP groups versus placebo.*

FDA Label Image

Figure 4 (E8695a1d Fd85 4639 81ff Bab10676ebd9 05)

A scatter plot chart displaying the percentage difference versus daily dose (mg) for Gabapentin. The graph compares data points from three different studies labeled as study a (black squares), study b (gray squares), and study c (white squares). The x-axis represents daily dose in milligrams, ranging approximately from 600 to 1900 mg, and the y-axis shows the difference percentage ranging from 2% to 22%.*

FDA Label Image

Company Logo (E8695a1d Fd85 4639 81ff Bab10676ebd9 06)

Chemical structure of gabapentin, showing its molecular configuration with a cyclohexane ring and attached amino and carboxyl groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.